WO2024028508A3 - Anticorps du récepteur 1 de type anti-chimiokine ou fragment de liaison à l'antigène de celui-ci destiné à être utilisé dans le traitement d'états associés à une nétose - Google Patents
Anticorps du récepteur 1 de type anti-chimiokine ou fragment de liaison à l'antigène de celui-ci destiné à être utilisé dans le traitement d'états associés à une nétose Download PDFInfo
- Publication number
- WO2024028508A3 WO2024028508A3 PCT/EP2023/071747 EP2023071747W WO2024028508A3 WO 2024028508 A3 WO2024028508 A3 WO 2024028508A3 EP 2023071747 W EP2023071747 W EP 2023071747W WO 2024028508 A3 WO2024028508 A3 WO 2024028508A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- netosis
- antigen
- antibody
- receptor
- treatment
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 2
- 102000036639 antigens Human genes 0.000 title abstract 2
- 108091007433 antigens Proteins 0.000 title abstract 2
- 239000012634 fragment Substances 0.000 title abstract 2
- 238000009169 immunotherapy Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
L'invention se rapporte au domaine de l'immunothérapie. La présente invention concerne un anticorps anti-récepteur de type chémérine 1 ou un fragment de liaison à l'antigène de celui-ci destiné à être utilisé dans le traitement d'une affection associée à une occurrence élevée de nétose.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22306192.0 | 2022-08-05 | ||
EP22306192 | 2022-08-05 | ||
EP23305971 | 2023-06-19 | ||
EP23305971.6 | 2023-06-19 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2024028508A2 WO2024028508A2 (fr) | 2024-02-08 |
WO2024028508A3 true WO2024028508A3 (fr) | 2024-04-18 |
Family
ID=87569973
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2023/071747 WO2024028508A2 (fr) | 2022-08-05 | 2023-08-04 | Anticorps du récepteur 1 de type anti-chimiokine ou fragment de liaison à l'antigène de celui-ci destiné à être utilisé dans le traitement d'états associés à une nétose |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024028508A2 (fr) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019193029A1 (fr) * | 2018-04-03 | 2019-10-10 | Ose Immunotherapeutics | Anticorps dirigés contre le récepteur 1 des chimiokines et leurs utilisations thérapeutiques |
EP3804754A1 (fr) * | 2019-10-09 | 2021-04-14 | OSE Immunotherapeutics | Agonistes cmklr1 ayant une capacité de type résolvine e1 et leurs applications thérapeutiques |
WO2021069709A1 (fr) * | 2019-10-09 | 2021-04-15 | Ose Immunotherapeutics | Anticorps humanisés du récepteur 1 de type anti-chimiokine et leurs utilisations thérapeutiques |
-
2023
- 2023-08-04 WO PCT/EP2023/071747 patent/WO2024028508A2/fr unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019193029A1 (fr) * | 2018-04-03 | 2019-10-10 | Ose Immunotherapeutics | Anticorps dirigés contre le récepteur 1 des chimiokines et leurs utilisations thérapeutiques |
EP3804754A1 (fr) * | 2019-10-09 | 2021-04-14 | OSE Immunotherapeutics | Agonistes cmklr1 ayant une capacité de type résolvine e1 et leurs applications thérapeutiques |
WO2021069709A1 (fr) * | 2019-10-09 | 2021-04-15 | Ose Immunotherapeutics | Anticorps humanisés du récepteur 1 de type anti-chimiokine et leurs utilisations thérapeutiques |
Non-Patent Citations (2)
Title |
---|
PEREZ DE LA LASTRA ET AL: "Epitope mapping of 10 monoclonal antibodies against the pig analogue of human membrane cofactor protein (MCP)", CANCER RESEARCH, vol. 96, no. 4, 1 April 1999 (1999-04-01), GB, pages 663 - 670, XP055572134, ISSN: 0019-2805, DOI: 10.1046/j.1365-2567.1999.00732.x * |
SUNGWHAN F. OH ET AL: "Pro-resolving actions and stereoselective biosynthesis of 18S E-series resolvins in human leukocytes and murine inflammation", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 121, no. 2, 1 February 2011 (2011-02-01), GB, pages 569 - 581, XP055628560, ISSN: 0021-9738, DOI: 10.1172/JCI42545 * |
Also Published As
Publication number | Publication date |
---|---|
WO2024028508A2 (fr) | 2024-02-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2020039321A8 (fr) | Anticorps anti-gdf15, compositions et procédés d'utilisation | |
WO2012166617A3 (fr) | Méthodes, compositions et trousses pour le traitement du cancer | |
WO2019014328A3 (fr) | Anticorps agonistes qui lient cd137 humain et leurs utilisations | |
WO2007056539A3 (fr) | Prevention et traitement de l'enterocolite associee a un traitement par anticorps anti-ctla-4 | |
AU2019206958A1 (en) | PD-L1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof | |
AU2015287227A8 (en) | Immune-stimulating monoclonal antibodies against human interleukin-2 | |
WO2020014473A8 (fr) | INHIBITEURS DE TGFβ1 ET LEUR UTILISATION | |
PH12020551661A1 (en) | Anti-pd-l1 antibody and use thereof | |
WO2019028182A3 (fr) | Traitement du cancer à l'aide d'anticorps se liant au récepteur cd134 humain (ox40) | |
MX2022007676A (es) | Anticuerpos caninizados biespecificos para tratar dermatitis atopica. | |
EP4049684A4 (fr) | Anticorps humanisé marqué par ri | |
WO2020006374A3 (fr) | Anticorps anti-sirp-bêta1 et procédés d'utilisation associés | |
EP3922647A4 (fr) | Anticorps anti-pd-1, fragment de liaison à l'antigène de celui-ci et utilisation pharmaceutique associée | |
WO2021022083A3 (fr) | Anticorps anti-ms4a4a et leurs procédés d'utilisation | |
NZ595863A (en) | Antibodies to egfl7 and methods for their use | |
WO2020257289A3 (fr) | Molécules d'anticorps humanisés se liant à cd138 et leurs utilisations | |
NZ728981A (en) | Anti-ceramide antibodies | |
WO2016145385A3 (fr) | Épitopes protecteurs pan-ebola et pan-filovirus, anticorps et cocktails d'anticorps | |
EP4023673A4 (fr) | Anticorps monoclonal humanisé ciblant bcma et ayant une réactivité croisée singe/etre humain | |
EP4043490A4 (fr) | Fragment d'anticorps fab anti-vegf humanisé et son utilisation | |
CR20230581A (es) | Anticuerpos anti-CCR8 y usos de los mismos | |
MX2022004312A (es) | Anticuerpos humanizados anti-receptor tipo quimiocina 1 y sus aplicaciones terapeuticas. | |
WO2017156423A3 (fr) | Cocktails d'anticorps largement protecteurs pour le traitement de la fièvre hémorragique à filovirus | |
WO2024028508A3 (fr) | Anticorps du récepteur 1 de type anti-chimiokine ou fragment de liaison à l'antigène de celui-ci destiné à être utilisé dans le traitement d'états associés à une nétose | |
MX2021000688A (es) | Anticuerpos anti-cd40 y usos de los mismos. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23753889 Country of ref document: EP Kind code of ref document: A2 |